Ana Fortuna

List of Publications by Citations

93 papers	2,016 citations	25 h-index	42 g-index
100 ext. papers	2,493 ext. citations	4.6 avg, IF	5.2 L-index

#	Paper	IF	Citations
93	Intranasal drug delivery: how, why and what for?. *Journal of Pharmacy and Pharmaceutical Sciences*, **2009**, 12, 288-311	3.4	313
92	Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 87, 409-32	5.7	171
91	Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review. *Analytica Chimica Acta*, **2013**, 768, 12-34	6.6	127
90	Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 88, 8-27	5.7	95
89	Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review. *Analytical and Bioanalytical Chemistry*, **2012**, 403, 93-129	4.4	62
88	Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. *European Journal of Pharmaceutical Sciences*, **2014**, 60, 32-9	5.1	60
87	First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life*	3.2	55
86	Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology. *Phytochemistry Reviews*, **2016**, 15, 51-85	7.7	51
85	Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. *Pharmaceuticals*, **2019**, 12,	5.2	49
84	Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. *Analytical and Bioanalytical Chemistry*, **2010**, 397, 1605-15	4.4	45
83	Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. *International Journal of Pharmaceutics*, **2015**, 490, 39-46	6.5	42
82	Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11-epoxide and licarbazepine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2014**, 971, 20-9	3.2	41
81	A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis. *Bioanalysis*, **2013**, 5, 1409-42	2.1	40
80	Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. *Current Drug Safety*, **2014**, 9, 89-105	1.4	37
79	Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. *Epilepsia*, **2012**, 53, 529-38	6.4	35
78	Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. *British Journal of Clinical Pharmacology*, **2020**, 86, 533-547	3.8	33
77	Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. *Phytochemistry Reviews*, **2015**, 14, 233-272	7.7	31

76	Rethinking carbamazepine oral delivery using polymer-lipid hybrid nanoparticles. *International Journal of Pharmaceutics*, **2019**, 554, 352-365	6.5	31
75	Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application. *Biomedical Chromatography*, **2014**, 28, 27-58	1.7	29
74	Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. *Biomedical Chromatography*, **2007**, 21, 1127-34	1.7	29
73	Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II. *Journal of Clinical Medicine*, **2019**, 8,	5.1	28
72	A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. *International Journal of Pharmaceutics*, **2016**, 501, 102-11	6.5	28
71	Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. *Epilepsy Research*, **2013**, 107, 37-50	3	28
70	Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. *British Journal of Pharmacology*, **2020**, 177, 2215-2239	8.6	26
69	First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2013**, 930, 104-11	3.2	26
68	ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. *Pharmacological Research*, **2019**, 144, 357-376	10.2	25
67	Optimization of a parallel artificial membrane permeability assay for the fast and simultaneous prediction of human intestinal absorption and plasma protein binding of drug candidates: application to dibenz[b,f]azepine-5-carboxamide derivatives. *Journal of Pharmaceutical Sciences*, **2012**, 101, 530-40	3.9	25
66	Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs. *Current Drug Metabolism*, **2016**, 17, 628-47	3.5	25
65	Nose-to-brain delivery of levetiracetam after intranasal administration to mice. *International Journal of Pharmaceutics*, **2019**, 564, 329-339	6.5	21
64	In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. *Epilepsy Research*, **2018**, 146, 63-86	3	21
63	Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs. *Food Research International*, **2018**, 103, 110-120	7	19
62	First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats - a pharmacokinetics study. *Analyst, The*, **2019**, 144, 2062-2079	5	17
61	Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma. *Biomedical Chromatography*, **2011**, 25, 535-41	1.7	17
60	Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. *Bioanalysis*, **2018**, 10, 541-557	2.1	15
59	Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. *Journal of Pharmaceutical Analysis*, **2019**, 9, 143-155	14	14

58	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. *Analytica Chimica Acta*, **2019**, 1076, 18-31	6.6	14
57	A chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: eslicarbazepine acetate, carbamazepine and main metabolites. *Journal of Separation Science*, **2011**, 34, 1391-401	3.4	14
56	In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. *Journal of Bioequivalence & Bioavailability*, **2011**, 01,	1.5	14
55	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol--Methyltransferase Inhibitors. *Drug Metabolism and Disposition*, **2017**, 45, 1282-1291	4	13
54	Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel. *European Journal of Pharmaceutical Sciences*, **2017**, 97, 30-37	5.1	13
53	Determination of catecholamines and endogenous related compounds in rat brain tissue exploring their native fluorescence and liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2017**, 1049-1050, 51-59	3.2	12
52	Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. *Drug Discovery Today*, **2019**, 24, 1911-1923	8.8	12
51	Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against Trypanosoma cruzi through semi-synthetic and simplified analogues of licarin A. *Scientific Reports*, **2020**, 10, 5467	4.9	12
50	A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain. *Biomedical Chromatography*, **2012**, 26, 384-92	1.7	12
49	Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, 181, 113109	3.5	11
48	Binding of licarbazepine enantiomers to mouse and human plasma proteins. *Biopharmaceutics and Drug Disposition*, **2010**, 31, 362-6	1.7	10
47	QbD-driven development of intranasal lipid nanoparticles for depression treatment. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 153, 106-120	5.7	9
46	Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: A tool to support pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2019**, 1124, 340-348	3.2	9
45	Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. *Therapeutic Drug Monitoring*, **2010**, 32, 512-6	3.2	9
44	An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. *Analyst, The*, **2013**, 138, 2463-9	5	8
43	Development and full validation of an HPLC methodology to quantify atorvastatin and curcumin after their intranasal co-delivery to mice. *Biomedical Chromatography*, **2019**, 33, e4621	1.7	7
42	Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration. *Pharmaceutical Research*, **2020**, 37, 74	4.5	7
41	Herb-drug pharmacokinetic interaction between carica papaya extract and amiodarone in rats. *Journal of Pharmacy and Pharmaceutical Sciences*, **2014**, 17, 302-15	3.4	7

40	Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats. *Drug and Chemical Toxicology*, **2021**, 44, 458-469	2.3	6
39	Development and validation of an HPLC-FLD technique for colistin quantification and its plasma monitoring in hospitalized patients. *Analytical Methods*, **2018**, 10, 389-396	3.2	6
38	Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices. *Biomedical Chromatography*, **2016**, 30, 312-22	1.7	6
37	Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays. *European Journal of Pharmaceutical Sciences*, **2017**, 109, 334-346	5.1	5
36	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. *Neuropharmacology*, **2017**, 125, 146-155	5.5	5
35	Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders. *Current Pharmaceutical Design*, **2020**, 26, 594-619	3.3	5
34	Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective. *Current Drug Metabolism*, **2018**, 19, 1021-1041	3.5	5
33	Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth impairment. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 155, 177-189	5.7	5
32	Cystic fibrosis: Physiopathology and the latest pharmacological treatments. *Pharmacological Research*, **2020**, 162, 105267	10.2	5
31	P-glycoprotein Mediated Efflux Modulators of Plant Origin: A Short Review. *Natural Product Communications*, **2016**, 11, 1934578X1601100	0.9	5
30	In vitro assessment of the interactions of dopamine Ehydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. *European Journal of Pharmaceutical Sciences*, **2018**, 117, 35-40	5.1	4
29	In Vitro?In Vivo Correlation (IVIVC): A Strategic Tool in Drug Development. *Journal of Bioequivalence & Bioavailability*, **2011**, 8,	1.5	4
28	Salting-out assisted liquid-liquid extraction method optimized by design of experiments for the simultaneous high-performance liquid chromatography analysis of perampanel and stiripentol in mouse matrices. *Journal of Separation Science*, **2020**, 43, 4289-4304	3.4	4
27	Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review. *Journal of Pharmaceutical Analysis*, **2021**, 11, 405-421	14	4
26	Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. *Toxicology and Applied Pharmacology*, **2017**, 323, 9-15	4.6	3
25	Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study. *Pharmaceutical Research*, **2017**, 34, 2260-2269	4.5	3
24	Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: Evaluation.. *Frontiers in Pharmacology*, **2021**, 12, 751321	5.6	3
23	HPLC method for the determination of antiepileptic drugs in human saliva and its application in therapeutic drug monitoring. *Journal of Pharmaceutical and Biomedical Analysis*, **2021**, 197, 113961	3.5	3

22	A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. *International Journal of Pharmaceutics*, **2021**, 593, 120161	6.5	3
21	Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.. *Ageing Research Reviews*, **2022**, 101612	12	3
20	Microextraction Techniques in LC-MS Bioanalysis **2019**, 98-116		2
19	Nose as a Route for Drug Delivery **2013**, 191-215		2
18	Pharmacokinetics of Cymbopogon Citratus Infusion in Rats after Single Oral Dose Administration. *SOJ Pharmacy & Pharmaceutical Sciences*, **2017**, 4, 1-9		2
17	Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders. *Pharmacological Research*, **2020**, 162, 105226	10.2	2
16	Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. *Pharmaceutics*, **2020**, 12,	6.4	2
15	Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. *Life Sciences*, **2021**, 275, 119342	6.8	2
14	Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1162, 122491	3.2	2
13	Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors. *Experimental and Clinical Psychopharmacology*, **2020**, 28, 589-600	3.2	1
12	Nanotechnological approaches in cancer: the role of celecoxib and disulfiram **2020**, 353-393		1
11	Is intranasal administration an opportunity for direct brain delivery of lacosamide?. *European Journal of Pharmaceutical Sciences*, **2021**, 157, 105632	5.1	1
10	Deciphering specific miRNAs in brain tumors: a 5-miRNA signature in glioblastoma.. *Molecular Genetics and Genomics*, **2022**, 297, 507	3.1	1
9	Study of the metabolic stability profiles of perampanel, rufinamide and stiripentol and prediction of drug interactions using HepaRG cells as an in vitro human model. *Toxicology in Vitro*, **2022**, 82, 105389	3.6	1
8	Real-world clinical characterization of subjects with depression treated with antidepressant drugs focused on (non-)genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study. *Experimental and Clinical Psychopharmacology*, **2020**, 28, 202-215	3.2	0
7	Expediting Disulfiram Assays through a Systematic Analytical Quality by Design Approach. *Chemosensors*, **2021**, 9, 172	4	0
6	The essential oil from the fruits of Peucedanum oreoselinum (L.) Moench (Apiaceae) as a natural source of P-glycoprotein inhibitors. *Journal of Herbal Medicine*, **2021**, 29, 100482	2.3	0
5	Intranasal delivery of lipid-based nanosystems as a promising approach for brain targeting of the new-generation antiepileptic drug perampanel. *International Journal of Pharmaceutics*, **2022**, 622, 121853	6.5	0

List of Publications

4	2.1 Pharmacokinetics and Bioanalysis to Improve Drug Development **2015**, 62-118	
3	Establishing Orthotopic Xenograft Glioblastoma Models for Use in Preclinical Development. *Neuromethods*, **2021**, 281-296	0.4
2	Novel Routes to Accessing the Brain: Intranasal Administration **2021**, 39-72	
1	Understanding Brain Delivery **2021**, 9-38	